Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol

Cardiology (Switzerland)

Volumn 88, Issue 2, 1997, Pages 160-165

  Sasaki, S ^a   Nakagawa, M ^a   Nakata, T ^a   Endo, N ^b   Miyao, K ^c   Kitamura, K ^d   Fukuyama, M ^e   Kitani, T ^f   Yamada, C ^g  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO FIRST RED CROSS HOSPITAL   (Japan)

^c KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^d Kyoto Teishin Hospital   (Japan)

^e Social Insurance Kyoto Hospital   (Japan)

^f Kyoto Interdisciplinary Institute of Community Health   (Japan)

^g KYOTO INDUSTRIAL HEALTH ASSOCIATION   (Japan)

Author keywords

3 Hydroxy 3 methylglutaryl; Coenzyme A reductase inhibitors; Fluvastatin; Hyperlipidemia; Probucol

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; APOLIPOPROTEIN C; APOLIPOPROTEIN E; CHOLESTEROL; FLUINDOSTATIN; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBUCOL; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031044689     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177324     Document Type: Article

References (21)

1. Yamamoto A. Matsuzawa Y. Yokoyama S. Fu-nahashi T. Yamamura T, Kishino B: HfTccts of probucol on xanthomata regression in familial hypercholesterolemia. Am.J Cardiol 1986:57: 29H-35H.
2. Durrington PN. Miller JP: Double-blind, placebo-controlled. cross-ovcr trial of probucol in heterozygous familial hypercholestcrolacmia. Atherosclerosis 1985:55:187-194.
3. Buckley MMT, Goa KL. Price AH, Brogdcn RN: Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolemia. Drugs 1989:37:761-800.
4. Steinberg D. Parthasarathy S. Carew TE. Khoo JC. Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989:320: 915-924.
5. Walldius G, Erikson U. Olsson AG. Bergstrand L. Hadell K. Johannson J. Kaijser E. Lassvik C. Molgaard J. Nilsson S: The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994:74:875-883.
6. Davignon J: Medical management ofhyperlip-idemia and the role of probucol. Am J Cardiol 1986:57:22H-28H.
7. Yamamoto A. Yokoyama S. Yamamura T: Combined drug treatment and plasmapheresis for familial hypercholesterolemia; in Fears R (cd): Pharmacological Control of Hyperlipidemia. Barcelona. Prous. 1986, pp 333-342.
8. Witztum JL. Simmons D. Steinberg D. Beltz WF. Wcinreb R. Young SG. Lester P. Kelly N. Juliano J: Intensive combination drug therapy of familial hypercholesterolemia with lovasta-lin. probucol. And colestipol hydrochloride. Circulation 1989:79:16-28.
9. Anderson TJ. Meredith IT. Yeung AC. Frei B. Selwyn AP. Ganz P: The effect of cholesterollowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-493.
10. Jacobson TA. Jokubaitis LA, Amorosa LF: Flu-vastalin and niacin in hypercholesterolemia: A preliminary report on gender differences in efficacy. Am J Med 1994:96:64S-68S.
11. Jacobson TA, Amorosa I.F: Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety. Am J Cardiol 1994:73:25D-29D.
12. Muratti EN. Peters TK, Leitersdorf E: Fluvastatin in familial hypercholesterolemia: A cohort analysis of the response to combination treatment. Am J Cardiol I994:73:30D-38D.
13. Batd J. Osc L, Hagen E. Duriez P. Pfister P. Fruchart JC. Dallongevillc J: Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group. Am J Cardiol I995:76:65A-70A.
14. Jacotot B. Banga JD. Waite R. Peters TK: Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-wcek multiccntcr study). French-Dutch Fluvastatin Study Group. Am J Cardiol 1995: 76:41A-46A.
15. Zavoral JH. Haggerty BJ. Winick AG, Berg-manr, SD: Efficacy of fluvastatin. A totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin in Long-Term Extension Trial. Am J Cardiol 1995:76:37A-40A.
16. Eliav O. Schurr D. Pfister P. Friedlander Y. Leitersdorf E: High-dose fluvastatin and beza-fibratc combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995;76:76A-79A.
17. Leitersdorf E. Muratti EN. Eliav O, Meiner V. Eiscnberg S, Dann EJ. Sehayck E. Peters TK. Stein Y: Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a lluvastatin-cholestyramine combination. Am J Med 1994;96:401-407.
18. Spence JD. Munoz CE. Hendricks L, Latchin-ian L. Khouri HE: Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995:76:80A-83A.
19. Leitersdorf E. Muratti EN. Eliav O, Peters TK: Efficacy and safety of triple therapy (fluvasta-tin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995:76:84A-88A.
20. East C. Alivizatos PA. Grundy SM. Jones PH. Farmer J A: Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation (letter). N Engl J Med 1988:318:47-48.
21. Pierce LR. Wysowski DK. Gross TP. Myopathy and rhabdomyolysis associated with lovas-tatin-gemfibrozil combination therapy. JAMA 1990:264:71-75.